[Comunicado de imprensa – Ainda não publicado] CureVac falha como vacina contra COVID-19 em estudo, com 47% de eficácia.

CureVac Fails in Pivotal COVID-19 Vaccine Trial With 47% Efficacy – AP / Reuters

Ver também: CureVac’s COVID-19 shot just failed in a large trial, a major setback for the Gates-backed biotech – Insider

Comunicado de imprensa: CureVac provides update on phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV

Comentário no Twitter (fio – clique para saber mais)

Bad new for CureVac's vaccine: it didn't make it over the efficacy bar in its 2nd interim analysis – only 47%. Not bad enough to be out for the count – it's 134 events (symptomatic Covid-19) & final is at 185 – but ….1/2 https://t.co/4GsLzgP7AT HT @noviceprize @megtirrell

— Hilda Bastian, PhD (@hildabast) June 16, 2021